UroGen Pharma financials
$40.45−1.10%
Close Sep 29, 2026 · split-adjustedRevenue
Net income
Income statement & cash flow
| Quarter | Q2 '26 Jun 30 | Q1 '26 Mar 31 | Q4 '25 Dec 31 | Q3 '25 Sep 30 | Q2 '25 Jun 30 | Q1 '25 Mar 31 | Q4 '24 Dec 31 | Q3 '24 Sep 30 | Q2 '24 Jun 30 | Q1 '24 Mar 31 | Q4 '23 Dec 31 | Q3 '23 Sep 30 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $72.5M | $51.0M | $37.8M | $27.5M | $24.2M | $20.3M | $24.6M | $25.2M | $21.8M | $18.8M | $23.5M | $20.9M |
| Gross profit | $65.9M | $46.8M | $34.5M | $24.2M | $20.7M | $17.9M | $22.1M | $22.8M | $19.6M | $14.6M | $21.2M | $18.5M |
| Gross margin | 90.9% | 91.9% | 91.3% | 88.1% | 85.3% | 88.5% | 89.9% | 90.3% | 89.8% | 77.8% | 90.3% | 88.6% |
| Operating income | $111.0K | -$20.3M | -$19.1M | -$27.4M | -$41.4M | -$36.9M | -$27.7M | -$17.5M | -$25.8M | -$28.2M | -$14.6M | -$13.5M |
| Net income | -$14.4M | -$23.6M | -$26.4M | -$33.3M | -$49.9M | -$43.8M | -$37.5M | -$23.7M | -$33.4M | -$32.3M | -$26.0M | -$21.9M |
| Net margin | −19.8% | −46.3% | −69.7% | −121.3% | −206.2% | −216.5% | −152.7% | −93.9% | −152.9% | −171.9% | −110.6% | −104.9% |
| Diluted EPS | $-0.28 | $-0.47 | $-0.54 | $-0.69 | $-1.05 | $-0.92 | $-0.80 | $-0.51 | $-0.82 | $-0.87 | $-0.72 | $-0.68 |
| EBITDA | $189.0K | -$20.2M | -$19.0M | -$27.3M | -$41.4M | -$36.8M | -$27.6M | -$17.5M | -$25.8M | -$28.1M | -$14.4M | -$13.3M |
| Operating cash flow | -$33.0M | -$45.3M | -$38.3M | -$42.3M | -$39.8M | -$42.0M | -$13.6M | -$27.7M | -$23.7M | -$31.7M | -$13.0M | -$17.3M |
| Free cash flow | -$33.1M | -$45.4M | -$38.3M | -$42.4M | -$40.0M | -$42.1M | -$13.7M | -$27.8M | -$23.8M | -$31.7M | -$13.1M | -$17.4M |
| Diluted shares | 50.4M | 50.2M | 49.2M | 48.1M | 47.7M | 47.4M | 47.2M | 46.8M | 40.5M | 37.1M | 36.3M | 32.3M |
Balance sheet
| Period end | Jun 30 | Mar 31 | Dec 31 | Sep 30 | Jun 30 | Mar 31 |
|---|---|---|---|---|---|---|
| Cash & equivalents | $79.1M | $110.0M | $110.7M | $90.0M | $92.9M | $104.0M |
| Short-term investments | $28.8M | $30.3M | $9.7M | $37.0M | $64.0M | $91.9M |
| Total debt | $193.1M | $189.5M | $127.0M | $122.1M | $122.5M | $122.1M |
| Total assets | $252.6M | $253.7M | $200.5M | $185.0M | $208.7M | $247.6M |
| Total liabilities | $385.0M | $377.9M | $305.9M | $300.5M | $302.1M | $294.1M |
| Shareholders' equity | -$132.4M | -$124.3M | -$105.5M | -$115.4M | -$93.4M | -$46.5M |
From SEC filings via Massive. Fiscal periods follow the company's own calendar; free cash flow is operating cash flow minus capital expenditure.
Sources: Massive / Polygon daily aggregates (split-adjusted) · SEC filings via Massive · FINRA settlements via Massive · Financial Modeling Prep. Figures are dated where shown; research is informational, not investment advice. Methodology